Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.

Hematological oncology - 1 Dec 2017

Kasamatsu Tetsuhiro, Saitoh Takayuki, Ino Rumi, Gotoh Nanami, Mitsui Takeki, Shimizu Hiroaki, Matsumoto Morio, Sawamura Morio, Yokohama Akihiko, Handa Hiroshi, Tsukamoto Norifumi, Murakami Hirokazu

Abstract excerpt

Interleukin-10 (IL-10) and IL-10 receptor (IL-10R) single nucleotide polymorphisms have been implicated in the pathogenesis of many cancers. We investigated the influence of IL-10 -592C/A, IL-10RA I224V, and IL-10RB K47E on the risk of developing multiple myeloma (MM) and the clinical features of MM. We extracted the genomic DNA from 128 MM patients and 202 healthy controls and used polymerase chain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Bortezomib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Interleukin-10

Share to Multiple Myeloma

Share to Neoplasm Staging

Share to Survival Analysis

Share to Thalidomide

Source

Identifiers

PMID: 27405747
DOI: 10.1002/hon.2322

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.PMID 27405747Read ↗

IL17A and IL23R gene polymorphisms affect the clinical features and prognosis of patients with multiple myeloma.Semantic proximity Read ↗

Effect of Cytokine Genes in the Pathogenesis and on the Clinical Parameters for the Treatment of Multiple Myeloma.Semantic proximity Read ↗

Effect of interleukin-2 (IL-2) polymorphisms on multiple myeloma: IL-2RA rs2104286, IL-2 rs2069762 and rs2069763 polymorphisms.Semantic proximity Read ↗

Common variants in genes that mediate immunity and risk of multiple myeloma.Semantic proximity Read ↗

Role of cytokines in multiple myeloma: IL-1RN and IL-4 VNTR polymorphisms.Semantic proximity Read ↗

CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.Semantic proximity Read ↗

Association of interleukin-1A, interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms with multiple myeloma.Semantic proximity Read ↗

Genetic polymorphisms and multiple myeloma risk: a meta-analysis.Semantic proximity Read ↗

Prognostic Impact of IL17 A Gene Polymorphismson Egyptian Patients with Multiple Myeloma.Semantic proximity Read ↗

Polymorphisms within genes encoding Ikaros family proteins IKZF1 and IKZF3 in multiple myeloma patients treated with thalidomide.Semantic proximity Read ↗

Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival.Semantic proximity Read ↗

Interleukin-10 gene promoter polymorphisms in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.